Impact Of COVID-19 Pandemic On The Pattern Of Azithromycin Prescribing; A Review
DOI:
https://doi.org/10.3823/866Keywords:
Antibiotics, Antimicrobial resistance, Azithromycin, Consumption, COVID-19Abstract
Objective: Emergence of COVID-19 infection and its persistence globally for three years in a row (2020-2022) entailed several modifications in healthcare services, among which drug prescribing was an important outcome. This review aims to highlight changing trends in azithromycin prescribing during pandemic years.
Methods: PubMed database was systematically searched for combinations of the following keywords: Antibiotics; Antimicrobial resistance; Azithromycin; COVID-19.
Results: A total of 12 articles were included in this review. All included studies demonstrated a notable increase in azithromycin consumption during COVID-19 pandemic in Spain, Brazil, USA, India, Croatia, and Jordan. Healthcare systems worldwide should be prepared to address anticipated outcomes of increased azithromycin use particularly possible changing trends in azithromycin resistance, and systemic side effects of the drug.
References
Dar-Odeh N, Elsayed S, Babkair H, Abu-Hammad S, Althagafi N, et al. What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review. J Dent Sci. 2021 Jul;16(3): 806-816.
Abu-Hammad S, Dar-Odeh N, Abu-Hammad O. SARS-CoV-2 and oral ulcers: A causative agent or a predisposing factor? Oral Dis. 2022 Apr;28Suppl 1: 933-934.
Dar- Odeh N, Babkair H, Abu-Hammad S, Borzangy S, Abu-Hammad A, Abu-Hammad O. COVID-19: Present and Future Challenges for Dental Practice. Int J Environ Res Public Health. 2020 Apr 30;17(9): 3151..
Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, et al. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. JAMA2015 Nov 17;314(19): 2034-2044. doi: 10.1001/jama.2015.13896. Erratum in: JAMA 2016 Jan 12;315(2): 204. Erratum in: JAMA. 2016 Jan 26;315(4): 419..
Schögler A, Kopf BS, Edwards MR, Johnston SL, Casaulta C, et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. EurRespirJ 2015 Feb;45(2): 428-39..
Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, et al. virus cell tropism in the developing human brain and inhibition by azithromycin. ProcNatlAcadSci U S A 2016 Dec 13;113(50): 14408-14413.
Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et al. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. ACS Infect Dis. 2015 Jul 10;1(7): 317-26.
Bosseboeuf E, Aubry M, Nhan T, de Pina JJ, Rolain JM, et al. Azithromycin Inhibits the Replication of Zika Virus. J AntivirAntiretrovir. 2018;10: 6-11.
Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm. 1992 Feb;11(2): 137-52. Erratum in: Clin Pharm. 1992 Apr;11(4): 308..
Bleyzac N, Goutelle S, Bourguignon L, Tod M. Azithromycin for COVID-19: More Than Just an Antimicrobial? Clin Drug Investig. 2020 Aug;40(8): 683-686.
Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio Cuscó M, Ferrández O, Horcajada JP, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2021 Feb;19(2): 147-163.
Salman S, Rogerson SJ, Kose K, Griffin S, Gomorai S, Baiwog F, et al. Pharmacokinetic properties of azithromycin in pregnancy. Antimicrob Agents Chemother. 2010 Jan;54(1): 360-6..
Bizjak ED, Haug MT 3rd, Schilz RJ, Sarodia BD, Dresing JM. Intravenous azithromycin-induced ototoxicity. Pharmacotherapy. 1999 Feb;19(2): 245-8..
Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med. 2013 May;1(3): 262-74.
Zhang M, Xie M, Li S, Gao Y, Xue S, Huang H, et al. Electrophysiologic Studies on the Risks and Potential Mechanism Underlying the Proarrhythmic Nature of Azithromycin. CardiovascToxicol. 2017 Oct;17(4): 434-440..
Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice. Biomed Res Int. 2018 Oct 14;2018: 1574806
Buehrle DJ, Decker BK, Wagener MM, Adalja A, Singh N, McEllistrem MC, et al. Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter. Antimicrob Agents Chemother. 2020 Oct 20;64(11): e01011-20..
Dieringer TD, Furukawa D, Graber CJ, Stevens VW, Jones MM, Rubin MA, et al Inpatient antibiotic utilization in the Veterans' Health Administration during the coronavirus disease 2019 (COVID-19) pandemic. Infect Control HospEpidemiol. 2021 Jun;42(6): 751-753..
Nestler MJ, Godbout E, Lee K, Kim J, Noda AJ, Taylor P, et al. Impact of COVID-19 on pneumonia-focused antibiotic use at an academic medical center. Infect Control HospEpidemiol. 2021 Jul;42(7): 915-916.
Staub MB, Beaulieu RM, Graves J, Nelson GE. Changes in antimicrobial utilization during the coronavirus disease 2019 (COVID-19) pandemic after implementation of a multispecialty clinical guidance team. Infect Control HospEpidemiol. 2021 Jul;42(7): 810-816..
Rojas-Garcia P, Antoñanzas F. Analysis of the Prescription of Antibiotics During the Implementation of COVID-19 Personal Protection Measures in a Regional Health System. Clinicoecon Outcomes Res. 2021 Nov 15;13: 927-936.
Gonzalez-Zorn B. Antibiotic use in the COVID-19 crisis in Spain. ClinMicrobiol Infect. 2021 Apr;27(4): 646-647.
Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, Navarrete-Rouco ME, Masclans JR, Espona M, et al. Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic. Antibiotics (Basel). 2021 Jan 29;10(2): 132.
Grau S, Hernández S, Echeverría-Esnal D, Almendral A, Ferrer R, Limón E, et al; Catalan Infection Control and Antimicrobial Stewardship Program (VINCat-PROA). Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 Pandemic. Antibiotics (Basel). 2021 Aug 4;10(8): 943.
Sulis G, Batomen B, Kotwani A, Pai M, Gandra S. Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis. PLoS Med. 2021 Jul 1;18(7): e1003682..
Silva ARO, Salgado DR, Lopes LPN, Castanheira D, Emmerick ICM, Lima EC. Increased Use of Antibiotics in the Intensive Care Unit During Coronavirus Disease (COVID-19) Pandemic in a Brazilian Hospital. Front Pharmacol. 2021 Dec 10;12: 778386.
Bogdanić N, Močibob L, Vidović T, Soldo A, Begovać J. Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020. PLoS One. 2022 Feb 2;17(2): e0263437..
Al-Azzam S, Mhaidat NM, Banat HA, Alfaour M, Ahmad DS, Muller A,et al. An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan. Antibiotics (Basel). 2021 Jun 9;10(6): 690..
Gbinigie K, Frie K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open. 2020 Jun 23;4(2): 1327–1336.
Kricker JA, Page CP, Gardarsson FR, Baldursson O, Gudjonsson T, Parnham MJ. Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacol Rev. 2021 Oct;73(4): 233-262.
Zhu X, Ye T, Zhong H, Luo Y, Xu J, Zhang Q, et al. Distribution and Drug Resistance of Bacterial Pathogens Associated with Lower Respiratory Tract Infection in Children and the Effect of COVID-19 on the Distribution of Pathogens. Can J Infect Dis Med Microbiol. 2022; 1–17.
López-Jácome LE, Fernández-Rodríguez D, Franco-Cendejas R, Camacho-Ortiz A, Morfin-Otero MDR, Rodríguez-Noriega E, et al. Increment Antimicrobial Resistance During the COVID-19 Pandemic: Results from the Invifar Network. Microb Drug Resist. 2022 Mar;28(3): 338-345.
Hill A, Wang J, Levi J, Heath K, Fortunak J. Minimum costs to manufacture new treatments for COVID-19. J Virus Erad. 2020 Apr 30;6(2): 61-69.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Najla Dar-Odeh, Osama Abu-Hammad, Nebras althagafi, Shaden Abu-Hammad, Rawah Eshky, Ismail Abdouh, Mona Aboelnagga, Abdalla Abu-Hammad
This work is licensed under a Creative Commons Attribution 4.0 International License.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 3.0 License ©
Copyright policies & self-archiving
This is our Copyright Policy. We are a RoMEO green journal.
| Author's Pre-print: |  author can archive pre-print (ie pre-refereeing) |
| Author's Post-print: | author can archive post-print (ie final draft post-refereeing) |
| Publisher's Version/PDF: | author can archive publisher's version/PDF |
